Search

ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka


Keypoints: 

torka-pallawi-230207-02_rt2-1200x800

•⁠  ⁠POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
•⁠  ⁠inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
•⁠  ⁠Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
•⁠  ⁠ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.

In this episode of the Oncology Brothers podcast, we wrap up our series on the highlights from ASH 2024, focusing specifically on key studies in lymphoma. Drs. Rahul & Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center, who provides valuable insights into several important trials.

We begin with the POLARIX study, which evaluates the use of polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL). Dr. Torka discusses the study design, findings, and how she incorporates this treatment into her clinical practice, noting a modest but statistically significant improvement in progression-free survival (PFS) without a clear overall survival (OS) benefit.

Next, we delve into the inMIND study, which examines the combination of tafasitamab with lenalidomide and rituximab in the second-line setting for follicular lymphoma. Dr. Torka highlights the promising results, particularly in PFS, and discusses the manageable side effects associated with tafasitamab.

We then shift our focus to mantle cell lymphoma, discussing the Triangle study, which suggests that the addition of BTK inhibitors in induction and maintenance therapy may eliminate the need for transplant. Dr. Torka emphasizes the logistical challenges and side effects associated with transplants, making the case for BTK inhibitors as a more favorable option.

Finally, we explore the ENRICH study, which compares ibrutinib-rituximab to traditional chemoimmunotherapy. Dr. Torka raises important considerations regarding treatment choices, particularly for older patients, and the ongoing debate between time-limited versus continuous therapy.

Throughout the episode, we reflect on the rapid advancements in lymphoma treatment and the importance of adapting our clinical practices based on emerging data. We also touch on the significance of managing side effects, particularly with new agents like tafacitimab.

Join us as we navigate these exciting developments in oncology and discuss how they may impact patient care in the community setting. Thank you for tuning in!